Evidence map›Paper›PMID 37446782›Full record

ArticleMolecules (Basel, Switzerland)2023

Synthesis and Evaluation of

Kelly Lu, Chengcheng Zhang, Zhengxing Zhang, Hsiou-Ting Kuo, Nadine Colpo, François Bénard, Kuo-Shyan Lin

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Diagnostic efficacy of [BMC cancer · 2024
    Pooled it
  2. Clinical evaluation of [RSC advances · 2025
    Article
  3. Review
  4. Development and Characterization ofInternational journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kelly LuDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Chengcheng ZhangDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Zhengxing ZhangDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Hsiou-Ting KuoDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Nadine ColpoDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
François BénardDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0001-7995-3581
Kuo-Shyan LinDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0002-0739-0780
Terry Fox Research Institute · CAUniversity of British Columbia · CA

Funding

CIHR PJT-162243, PJT-180299 and PJT-180300
6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) is a well-validated prostate cancer marker but reported PSMA-targeted tracers derived from the Lys-urea-Glu pharmacophore including the clinically validated [

Indexed as

Prostatic NeoplasmsUreaAnimalsEdetic AcidHumansMaleMicePharmacophoreTissue DistributionTomography, Emission-Computed, Single-PhotonEDDAEdetic AcidUreaHYNICmolecular imagingprostate-specific membrane antigen (PSMA)single photon emission computed tomography (SPECT)technetium-99m

Identifiers

PMID37446782
PMCPMC10343272
OpenAlexW4382814339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.